The impact of embolization endpoints on the efficacy of uterine artery embolization for adenomyosis
article
OA: closed
CC0
AI-generated summary
This study found that the delayed embolization endpoint in uterine artery embolization for adenomyosis resulted in greater symptom relief compared to the standard endpoint, with no significant differences in other clinical outcomes.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: This study aimed to assess how embolization endpoints affect the efficacy of uterine artery embolization (UAE) for adenomyosis.
METHODS: In this single-center retrospective cohort study, patients treated with UAE from 2014-2018 received the standard embolization endpoint (SEE), while those from 2019-2022 received the delayed embolization endpoint (DEE). Clinical outcomes, including embolic microsphere volume, uterine volume, CA125 levels, hemoglobin, menstrual flow, dysmenorrhea, and postoperative complications, were compared between the groups.
RESULTS: At six months post-procedure, all patients showed significant improvement in clinical indicators (p < 0.01). Group DEE used significantly more embolic microspheres than Group SEE (p < 0.01) and achieved greater reductions in CA125, menstrual volume, and dysmenorrhea (p 0.05).
CONCLUSIONS: UAE is a safe and effective treatment for adenomyosis. Compared to the standard approach, the delayed embolization endpoint provides superior symptom relief and warrants broader clinical adoption.
My notes (saved in your browser only)
Outcome instruments
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (29)
- A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women via openalex
- Adenomyosis pathogenesis: insights from next-generation sequencing via openalex
- An update on uterine artery embolization for uterine leiomyomata and adenomyosis of the uterus via openalex
- Increased Angiogenesis and Lymphangiogenesis in Adenomyosis Visualized by Multiplex Immunohistochemistry via openalex
- Long‐term durability of uterine artery embolisation for treatment of symptomatic adenomyosis via openalex
- Long-Term Results of Uterine Artery Embolization for Symptomatic Adenomyosis via openalex
- MRI of Adenomyosis: Where Are We Today? via openalex
- Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases via openalex
- Pathology and Pathogenesis of Adenomyosis via openalex
- Total or Subtotal Hysterectomy for the Treatment of Endometriosis: A Review via openalex
- Uterine Artery Embolization for Adenomyosis via openalex
- Uterine Artery Embolization for Adenomyosis: Percentage of Necrosis Predicts Midterm Clinical Recurrence via openalex
- Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire via openalex
- Uterine Artery Embolization for Symptomatic Adenomyosis: A New Technical Development of the 1-2-3 Protocol and Predictive Factors of MR Imaging Affecting Outcomes via openalex
- W4402989420 via openalex
- W4403054391 via openalex
- W1974252360 via openalex
- W2002544923 via openalex
- W2041091095 via openalex
- W2048036760 via openalex
- W2075488838 via openalex
- W2314629735 via openalex
- W2319611721 via openalex
- W2470604858 via openalex
- W2966047758 via openalex
- W3192714526 via openalex
- W4308891075 via openalex
- W4324370650 via openalex
- W4391357691 via openalex
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-11T06:16:12.914779+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK